<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[dr. anthony Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/dr.+anthony.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to dr. anthony]]></description>
	<s:counts start="0" returned="2" found="2" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Rigel Pharmaceuticals: A Game Changer in the Works?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F145726-rigel-pharmaceuticals-a-game-changer-in-the-works%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Dr. Anthony submits: With the impending announcement of the Phase IIb data for Rigel's RIGL lead compound R-788, I thought I would share my analysis. Rheumatoid Arthritis is a chronic debilitating disease that requires life-long treatment, which makes it a lucrative market but also at the same time very competitive....]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 28 Jun 2009 01:31:38 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/dr.+anthony.html"><![CDATA[Dr. Anthony]]></category>
		<category domain="http://resources.bnet.com/topic/rigel+pharmaceuticals+inc..html"><![CDATA[Rigel Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RIGL</category>
		<category domain="tickers">RIGL</category>
	</item>
	<item>
		<title><![CDATA[Why I Doubt the FDA Will Approve Acorda's Fampridine]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F132889-why-i-doubt-the-fda-will-approve-acorda-s-fampridine%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Dr. Anthony submits: Yesterday there was an announcement that Acorda (NASDAQ: ACOR) has amended their NDA application for fampridine. After after taking a closer look at their Phase III study (MS-F203), here is a reason why come February 23, 2010 the FDA will provide a verdict of NOT APPROVED or...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 24 Apr 2009 12:52:33 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/dr.+anthony.html"><![CDATA[Dr. Anthony]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACOR</category>
		<category domain="tickers">ACOR</category>
	</item>
</channel>
</rss>
